uric acid and Dilatation, Pathologic studies

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.

Dilatation, Pathologic: The condition of an anatomical structure's being dilated beyond normal dimensions.

Research Excerpts

Excerpt	Relevance	Reference
"Uric acid (UA) is considered to be a powerful predictor of cardiovascular risk and hyperuricemia might be involved in the metabolic syndrome (MS)."	7.76	Relation of uric acid levels to aortic root dilatation in hypertensive patients with and without metabolic syndrome. ( Chen, XF; Du, YX; Fang, CF; Jiang, JJ; Lin, XF; Pu, ZX; Tang, LJ; Wang, JA, 2010)
"MPV, GGT and uric acid levels were significantly higher in subjects with stenotic coronary artery disease (CAD) and in subjects with both CAD and CAE compared with subjects with isolated CAE and subjects with normal coronary arteries (NCA)."	3.79	No relevant association between coronary artery ectasia and mean platelet volume, gamma-glutamyltransferase and uric acid levels. ( Akpek, M; Arınç, H; Baktır, AO; Karadağ, Z; Katlandur, H; Kaya, MG; Kurtul, S; Sağlam, H; Sarlı, B, 2013)
"This short-term prospective study included 40 patients with acute myocardial infarction (AMI) in whom we determined GGT activity, lipids, uric acid, homocysteine (Hcy), high sensitivity C-reactive protein (hsCRP) and left ventricular (LV) function on admission and on day 5 following AMI."	3.77	Is γ-glutamyl transferase activity a potential marker of left ventricular function during early postmyocardial infarction period? ( Dzubur, A; Hadzovic-Dzuvo, A; Jadric, R; Kiseljakovic, E; Lepara, O; Nakas-Icindic, E; Valjevac, A, 2011)
"Uric acid (UA) is considered to be a powerful predictor of cardiovascular risk and hyperuricemia might be involved in the metabolic syndrome (MS)."	3.76	Relation of uric acid levels to aortic root dilatation in hypertensive patients with and without metabolic syndrome. ( Chen, XF; Du, YX; Fang, CF; Jiang, JJ; Lin, XF; Pu, ZX; Tang, LJ; Wang, JA, 2010)
"Coronary artery ectasia was defined as a luminal dilatation of at least 1."	1.35	[Elevated serum uric acid levels in patients with isolated coronary artery ectasia]. ( Akçakoyun, M; Akpinar, I; Aksu, T; Balbay, Y; Cay, S; Cetin, M; Erbay, AR; Maden, O; Ozcan, F; Sen, N; Sökmen, E; Uygur, B, 2009)

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Flow-mediated Arterial Vasodilation

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (22.22)	29.6817
2010's	5 (55.56)	24.3611
2020's	2 (22.22)	2.80

Authors	Studies
Gaffo, AL	1
Calhoun, DA	1
Rahn, EJ	1
Oparil, S	1
Li, P	1
Dudenbostel, T	1
Feig, DI	1
Redden, DT	1
Muntner, P	1
Foster, PJ	1
Biggers-Clark, SR	1
Mudano, A	1
Sattui, SE	1
Saddekni, MB	1
Bridges, SL	1
Saag, KG	1
Yang, Z	1
Yuan, J	1
Cui, J	1
Guan, H	1
Qiao, S	1
Sarlı, B	1
Baktır, AO	1
Sağlam, H	1
Arınç, H	1
Kurtul, S	1
Karadağ, Z	1
Katlandur, H	1
Akpek, M	1
Kaya, MG	1
Sen, N	1
Ozcan, F	1
Uygur, B	1
Aksu, T	1
Akpinar, I	1
Cay, S	1
Cetin, M	2
Sökmen, E	1
Akçakoyun, M	2
Maden, O	1
Balbay, Y	1
Erbay, AR	1
Tang, LJ	1
Jiang, JJ	1
Chen, XF	1
Wang, JA	1
Lin, XF	1
Du, YX	1
Fang, CF	1
Pu, ZX	1
Esen, AM	1
Esen, O	1
Acar, G	1
Emiroglu, Y	1
Pala, S	1
Kargin, R	1
Karapinar, H	1
Ozcan, O	1
Barutcu, I	1
Valjevac, A	1
Dzubur, A	1
Nakas-Icindic, E	1
Hadzovic-Dzuvo, A	1
Lepara, O	1
Kiseljakovic, E	1
Jadric, R	1
Çanga, A	1
Kocaman, SA	1
Erdoğan, T	1
Durakoğlugil, ME	1
Çiçek, Y	1
Uğurlu, Y	1
Satiroğlu, Ö	1
Coria-Avila, GA	1
Barbosa-Vargas, E	1
Pfaus, JG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
University of Alabama at Birmingham CORT Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure[NCT02038179]	Phase 2/Phase 3	99 participants (Actual)	Interventional	2014-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Compare endothelial function as indexed by flow-mediated arterial vasodilation (FMD) within each phase of treatment (allopurinol 300 mg/day PO or placebo). Percent (%) change in FMD is calculated by comparing FMD (%) at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment FMD Values (%))

Change in Serum Levels of High Sensitivity C-reactive Protein

Intervention	percent change (Mean)
Allopurinol Phase	2.5
Placebo Phase	-0.1

Serum level of high sensitivity C-reactive protein will be reported as a change during treatment phase (allopurinol 300 mg/day PO or placebo). Change in serum level of C-reactive protein is calculated by comparing serum values at the end of each treatment phase to pre-treatment levels. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment serum levels)

Change in Systolic Blood Pressure (SBP)

Intervention	mg/L (Mean)
Allopurinol Phase	0.6
Placebo Phase	0.8

Compare systolic blood pressure (SBP) captured by wearing a 24 hour ambulatory blood pressure monitor during each phase of treatment (allopurinol 300 mg/day PO or placebo). Change in systolic blood pressure is calculated by comparing SBP at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment SBP)

Article	Year
Association of the lymphocyte-to-monocyte ratio, mean diameter of coronary arteries, and uric acid level with coronary slow flow in isolated coronary artery ectasia. BMC cardiovascular disorders, 2021, 03-30, Volume: 21, Issue:1 Topics: Adult; Aged; Biomarkers; Blood Flow Velocity; Coronary Angiography; Coronary Artery Disease; Coronar	2021
No relevant association between coronary artery ectasia and mean platelet volume, gamma-glutamyltransferase and uric acid levels. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2013, Volume: 41, Issue:7 Topics: Coronary Artery Disease; Dilatation, Pathologic; Female; gamma-Glutamyltransferase; Humans; Male; Me	2013
[Elevated serum uric acid levels in patients with isolated coronary artery ectasia]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37, Issue:7 Topics: Aged; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Vessel	2009
Relation of uric acid levels to aortic root dilatation in hypertensive patients with and without metabolic syndrome. Journal of Zhejiang University. Science. B, 2010, Volume: 11, Issue:8 Topics: Aged; Aortic Diseases; Blood Pressure; Cardiovascular Diseases; Dilatation, Pathologic; Echocardiogr	2010
Uric acid as a marker of oxidative stress in dilatation of the ascending aorta. American journal of hypertension, 2011, Volume: 24, Issue:2 Topics: Adult; Aged; Aorta; Aortic Aneurysm; Biomarkers; Case-Control Studies; Chi-Square Distribution; Dila	2011
Is γ-glutamyl transferase activity a potential marker of left ventricular function during early postmyocardial infarction period? Future cardiology, 2011, Volume: 7, Issue:5 Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Colorimetry; Creatine Kinase, MB Form; Dilatatio	2011
Increased epicardial adipose tissue thickness is correlated with ascending aortic diameter. The Tohoku journal of experimental medicine, 2012, Volume: 226, Issue:3 Topics: Adipose Tissue; Adult; Aorta; C-Reactive Protein; Cross-Sectional Studies; Dilatation, Pathologic; E	2012
Sudden bladder distention in a female rat. Lab animal, 2005, Volume: 34, Issue:6 Topics: Animals; Dilatation, Pathologic; Fatal Outcome; Female; Rats; Rats, Long-Evans; Rodent Diseases; Uri	2005

uric acid and Dilatation, Pathologic